XML 25 R10.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Revenue | 12 Months Ended
--- | ---
Jun. 30, 2022
Text block [abstract] |
Revenue | Note 5. Revenue
|  | Consolidated |
|  | 2022 A$’000 |  |  | 2021 A$’000 |  |  | 2020 A$’000 |
Licensing revenue |  |  | — |  |  |  | 15,183 |  |  |  | — |
Disaggregation of revenue The disaggregation of revenue from contracts with customers is as follows:
|  | Consolidated |
|  | 2022 A$’000 |  |  | 2021 A$’000 |  |  | 2020 A$’000 |
Geographical regions |  |  |  |  |  |  |  |  |  |  |  |
China |  |  | — |  |  |  | 10,006 |  |  |  | — |
Sweden |  |  | — |  |  |  | 5,177 |  |  |  | — |
|  |  | — |  |  |  | 15,183 |  |  |  | — |
Timing of revenue recognition |  |  |  |  |  |  |  |  |  |  |  |
Licensing revenue at a point in time |  |  | — |  |  |  | 15,183 |  |  |  | — |
During fiscal year 2021, the company recognized a total of US$11 million in accordance with the terms of the company’s license agreements with Oasmia Pharmaceutical AB and Simcere Pharmaceutical Group LTD. The terms of the license agreements are described in the following paragraphs. License Agreement with Oasmia Pharmaceutical AB In March 2021, the company entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1), a clinical stage drug candidate for the treatment of ovarian cancer. During fiscal 2021, Oasmia made an upfront payment of US$4 million with contingent milestones of up to US$42 million and double-digit royalties on commercial sales. License Agreement with Simcere Pharmaceutical Group Ltd. In March 2021, the company entered into a licensing agreement with Simcere Pharmaceutical Group LTD. to develop and commercialise the company’s investigational drug candidate, paxalisib, in Greater China. Under the terms of the agreement, Simcere assumed responsibility for the development, registration and commercialization of paxalisib in Greater China (a territory that includes Mainland China, Hong Kong, Macau and Taiwan). The company received an upfront payment of US$11 million comprising US$7 million in cash and a US$4 million equity investment, priced at a 20% premium to recent trading. The company will also receive contingent milestone payments of up to US$281 million for glioblastoma, with further milestones payable for indications beyond glioblastoma. Simcere will additionally pay mid-teen percentage royalties on commercial sales. During fiscal year 2022, the company did not recognise revenue from either license agreements described in the above paragraphs in accordance with the terms of the agreements and revenue recognition policy in accordance with note 2.

X
- Definition The entire disclosure for revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfRevenueExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block [abstract] + References No definition available. + Details
Name: | kzia_TextBlockAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration